AbbVie received a Complete Response Letter from the FDA concerning its biologics license application for trenibotulinumtoxinE (TrenibotE), a novel botulinum toxin with rapid onset and short duration. The FDA's request focuses solely on additional manufacturing process details, with no safety or efficacy concerns raised and no new clinical trials required. AbbVie plans to address the FDA's comments promptly and expects to submit a thorough response soon. Regulatory reviews in other countries are ongoing as expected.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
